Anti-masculinizing action of estradiol and cyproterone acetate: regulation of a protein fraction with phospholipase-A2 stimulatory and masculinizing activities.
Recently we have identified a protein fraction (55-63 K) from male and testosterone-exposed female mouse genital tract, which stimulates phospholipase A2 (PLA2) and induces masculine differentiation in an undifferentiated mouse genital explant, suggesting a role of this protein in the action of testosterone. In the current study we have further investigated the role of this protein by determining whether anti-masculinizing agents, namely, estradiol and cyproterone acetate, have any effect on the production of this protein. The results described here indicate that a protein fraction containing PLA2 stimulatory activity was present in both control male and estradiol- or cyproterone acetate-exposed male fetal genital tract. However the specific activity of the PLA2-stimulatory protein was significantly higher in the control males than in the experimental males. We did not find any major difference in the behavior of this protein fraction in various chromatographic steps except that in CM-sepharose column; the PLA2-stimulatory activity from the male preparation was eluted in two overlapping peaks with 0.3 and 0.25 M NaCl and that from the treated males was eluted only with 0.25 M NaCl. The SDS-gel analysis of this protein fraction revealed a doublet band (55 and 63 K) in control samples and primarily a 63 K band in experimental samples. The protein fraction from all these sources showed a significant difference in their biological activity. The control male preparation induced Wolffian duct whereas the estradiol sample was completely ineffective and the cyproterone acetate sample was partially effective in inducing Wolffian duct. Thus, it appears that the protein fraction has a role in the masculinizing action of testosterone.
Gupta
C
C
Department of Pediatric Nephrology, Children's Hospital of Pittsburgh, School of Medicine, University of Pittsburgh, PA 15213.
Wharton
V
V
Ellis
D
D
D000818:Animals; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000494:pharmacology; D017373:Cyproterone Acetate; D004591:Electrophoresis, Polyacrylamide Gel; D004789:Enzyme Activation; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D005837:Genitalia, Male / Q000187:drug effects / Q000201:enzymology / Q000254:growth & development*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009924:Organ Culture Techniques; D010741:Phospholipases A / Q000378:metabolism*; D054467:Phospholipases A2; D011506:Proteins / Q000378:metabolism*; D012733:Sex Differentiation / Q000187:drug effects*; D013379:Substrate Specificity; D014928:Wolffian Ducts / Q000187:drug effects / Q000254:growth & development
D011506:Proteins; C055324:phospholipase A2-activating protein; D017373:Cyproterone Acetate; D004958:Estradiol; D003534:Cyproterone; D010741:Phospholipases A; D054467:Phospholipases A2